Earnings ·
ORIC Pharmaceuticals reported second quarter 2026 financial results and operational updates
ORICOric Pharmaceuticals, Inc.
ORIC Pharmaceuticals reported second quarter 2026 financial results and operational updates. The company initiated the global Phase 3 Himalayas-1 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC), enrolling approximately 600 patients, with Bayer providing darolutamide at no cost under a collaboration agreement. Cash and investments totaled $387.6 million as of June 30, 2026, including $59.9 million from ATM proceeds, funding operations into the second half of 2028. R&D expenses were $36.3 million for the quarter, while net loss was $41.5 million. The company anticipates a rinzimetostat program update in late 2026 and enozertinib data presentations in October 2026. ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing oncology treatments to overcome therapeutic resistance.